Abstract
It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Current Vascular Pharmacology
Title: Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?
Volume: 5 Issue: 3
Author(s): Luis C.L. Correia
Affiliation:
Keywords: Statin therapy, statins, acute coronary syndromes, unstable angina, acute myocardial infarction, acute phase
Abstract: It has been claimed that early use of statins in acute coronary syndromes (ACS) protects patients against recurrent ischemic events. This protective effect takes place as early as 4 months after treatment initiation in non-ST elevation ACS, as reported in the MIRACL trial. Mechanisms such as improvement in endothelial function and inflammation are possible explanations for this early effect. These findings have been used to propose statins as part of the acute phase therapy. However, the use of statins during hospitalization is an unresolved issue, because there is a lack of evidence regarding the benefit of initiating therapy in the acute phase. Most randomized trials included patients after several days of the index event and did not report in-hospital outcome. This review critically discusses the use of statins in ACS and the level of evidence regarding their beneficial effect in acute phase treatment.
Export Options
About this article
Cite this article as:
Luis C.L. Correia , Is There a True Beneficial Effect of Statin Therapy in the Acute Phase of Unstable Angina or Myocardial Infarction?, Current Vascular Pharmacology 2007; 5 (3) . https://dx.doi.org/10.2174/157016107781024127
DOI https://dx.doi.org/10.2174/157016107781024127 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Toxics of Tobacco Smoke and Cardiovascular System: From Functional to Cellular Damage
Current Pharmaceutical Design Poly(ADP-Ribose) Polymerase Inhibitors: New Pharmacological Functions and Potential Clinical Implications
Current Pharmaceutical Design Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Adrenomedullins: Therapeutic Potential in Cardiovascular Disease
Current Hypertension Reviews Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery The Relationship Between Cleft Lip, Maxillary Hypoplasia, Hypoxia and Phenytoin
Current Pharmaceutical Design The Role of Cytokines in Pharmacological Modulation of Hepatic Ischemia/Reperfusion Injury
Current Pharmaceutical Design Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Infection, its Treatment and the Risk for Stroke
Current Vascular Pharmacology Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Radial Approach for Percutaneous Coronary Intervention
Reviews on Recent Clinical Trials Rheumatoid Arthritis: Cardiovascular Manifestations, Pathogenesis, and Therapy
Current Pharmaceutical Design Chemokines as Potential Therapeutic Targets in Atherosclerosis
Current Drug Targets Treatment of Atherosclerotic Renovascular Disease
Current Hypertension Reviews MiR-101 Attenuates Myocardial Infarction-induced Injury by Targeting DDIT4 to Regulate Autophagy
Current Neurovascular Research Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Low Molecular Weight Compounds with Transition Metals as Free Radical Scavengers and Novel Therapeutic Agents
Cardiovascular & Hematological Agents in Medicinal Chemistry